SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Nordenskjöld Bo 1940 )
 

Search: WFRF:(Nordenskjöld Bo 1940 ) > Expression of COX-2...

  • Gunnarsson, Cecilia,1970-Linköpings universitet,Onkologi,Hälsouniversitetet (author)

Expression of COX-2 and steroid converting enzymes in breast cancer

  • Article/chapterEnglish2006

Publisher, publication year, extent ...

  • 2006
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-35971
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-35971URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:112175381URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • COX-2 is upregulated in many breast tumors, and one of the products of COX-2 is PGE2 that is suggested to upregulate aromatase through cAMP signaling in breast cancer. Although aromatase can increase the estrogen levels in tumors, 17β-hydroxysteroid dehydrogenase (17HSD) activity is finally needed for the estrone/estradiol regulation. The aim of this study was to investigate if the protein expression of enzymes involved in estrogen synthesis shows covariation with the expression of COX-2. We also wanted to correlate these results with prognosis. We analyzed the expression of COX-2, aromatase, 17HSD1 and 17HSD2 with immunohistochemistry using tissue microarrays composed of 356 primary breast tumors. In the present study COX-2 was correlated to aromatase (P<0.00001), 17HSD1 (P=0.0073), and 17HSD2 (P<0.00001). Patients with ER positive tumors expressing low amounts of 17HSD2 had decreased breast cancer survival (P=0.013). Elevated expression of COX-2 and aromatase was more frequent among larger tumors (P=0.017 and P=0.013). COX-2 expression correlates with the levels of the examined steroid converting enzymes and may contribute to increased estrogen levels in the tumor. In breast cancer cells, the regulatory function of 17HSD2 could be lost, and in the present study patients with low or non-detectable levels of 17HSD2 had worse prognosis than had breast cancer patients with higher levels of the enzyme.

Subject headings and genre

  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Jansson, Agneta,1973-Linköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)agnja94 (author)
  • Holmlund, BirgittaLinköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)birho30 (author)
  • Ferraud, LilianneLinköpings universitet,Onkologi,Hälsouniversitetet (author)
  • Nordenskjöld, Bo,1940-Linköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)bono64 (author)
  • Rutqvist, Lars ErikClinic of Oncology, Karolinska University Hospital, Stockholm, Sweden (author)
  • Skoog, LambertKarolinska Institutet (author)
  • Stål, Olle,1952-Linköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)ollst87 (author)
  • Linköpings universitetOnkologi (creator_code:org_t)

Related titles

  • In:Oncology Reports16:2, s. 219-2241021-335X1791-2431

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view